| Literature DB >> 17554341 |
S K Sedimbi1, X R Luo, C B Sanjeevi, Ake Lernmark, Mona Landin-Olsson, Hans Arnqvist, Elizabeth Björck, Lennarth Nyström, Lars Olof Ohlson, Bengt Scherstén, Jan Ostman, M Aili, L E Bååth, E Carlsson, H Edenwall, G Forsander, B W Granström, I Gustavsson, R Hanås, L Hellenberg, H Hellgren, E Holmberg, H Hörnell, Sten-A Ivarsson, C Johansson, G Jonsell, K Kockum, B Lindblad, A Lindh, J Ludvigsson, U Myrdal, J Neiderud, K Segnestam, S Sjöblad, L Skogsberg, L Strömberg, U Ståhle, B Thalme, K Tullus, T Tuvemo, M Wallensteen, O Westphal, Gisela Dahlquist, J Aman.
Abstract
SUMO4 M55V, located in IDDM5, has been a focus for debate because of its association to type I diabetes (TIDM) in Asians but not in Caucasians. The current study aims to test the significance of M55V association to TIDM in a large cohort of Swedish Caucasians, and to test whether M55V is associated in those carrying human leukocyte antigen (HLA) class II molecules. A total of 673 TIDM patients and 535 age- and sex-matched healthy controls were included in the study. PCR-RFLP was performed to identify the genotype and allele variations. Our data suggest that SUMO4 M55V is not associated with susceptibility to TIDM by itself. When we stratified our patients and controls based on heterozygosity for HLA-DR3/DR4 and SUMO4 genotypes, we found that presence of SUMO4 GG increased further the relative risk conferred by HLA-DR3/DR4 to TIDM, whereas SUMO4 AA decreased the risk. From the current study, we conclude that SUMO4 M55V is associated with TIDM in association with high-risk HLA-DR3 and DR4, but not by itself.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17554341 DOI： 10.1038/sj.gene.6364406
Source DB: PubMed Journal: Genes Immun ISSN： 1466-4879 Impact factor: 2.676